After nearly a decade of legislative efforts, US President Barack Obama on Friday (September 16) signed the America Invents Act, historic patent reform legislation that aims to help American entrepreneurs and businesses bring their inventions to market sooner, creating new businesses and new jobs (The Pharma Letters passim). The President also announced additional steps that will help convert the ideas from America’s universities and research labs into new products, expanding the USA’s economy and creating 21st century jobs.
“I am pleased to sign the America Invents Act. This much-needed reform will speed up the patent process so that innovators and entrepreneurs can turn a new invention into a business as quickly as possible,” said President Obama, adding: “Here in America, our creativity has always set us apart, and in order to continue to grow our economy, we need to encourage that spirit wherever we find it.”
The new Act represents the most significant reform of the Patent Act since 1952. It will give a boost to American companies and inventors who have suffered costly delays and unnecessary litigation, and let them focus instead on innovation and job creation. These reforms were also a key recommendation of the President’s Council on Jobs and Competitiveness, which has been a strong advocate for patent reform as a way to support job creation and strengthen America’s competitiveness in the global economy.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze